NYSE:DHR

Curiox Biosystems and Beckman Coulter Life Sciences Announce a Partnership Combining C-FREE™ Technology with DURA Innovations for Hands-Free Washed Sample Preparation for Flow Cytometry

Retrieved on: 
Friday, May 3, 2024
Laboratory, Head, Laminar, Partnership, Doctor of Philosophy, Research, Vaccine, Automation, Flow cytometry

The agreement combines the Laminar flow-based gentle liquid exchange technology known as C-FREE™ technology from Curiox with the comprehensive suite of DURAClone dry pre-formulated antibody panels and customized DURA Innovations dry reagent antibody cocktails from Beckman Coulter Life Sciences.

Key Points: 
  • The agreement combines the Laminar flow-based gentle liquid exchange technology known as C-FREE™ technology from Curiox with the comprehensive suite of DURAClone dry pre-formulated antibody panels and customized DURA Innovations dry reagent antibody cocktails from Beckman Coulter Life Sciences.
  • This workflow solution overcomes longstanding challenges faced by researchers worldwide, including the need for highly standardized, reproducible, and automated sample preparation for flow cytometry laboratories.
  • "Our alliance with Beckman Coulter Life Sciences is not just about combining technologies; it's about combining our strengths to empower the scientific community," said Namyong Kim.
  • "This partnership presents an exciting step forward in redefining the standards of quality and efficiency in flow cytometry research.

Danaher Reports First Quarter 2024 Results

Retrieved on: 
Tuesday, April 23, 2024
Cepheid variable, Webcast, Danaher Corporation, GAAP, Conference, DHR, Bank

WASHINGTON, April 23, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended March 29, 2024.

Key Points: 
  • WASHINGTON, April 23, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended March 29, 2024.
  • For the second quarter 2024, the Company anticipates that non-GAAP core revenue will be down mid-single digits year-over-year.
  • Danaher will discuss its first quarter results and financial guidance for the second quarter and full year 2024 during its quarterly investor conference call today starting at 8:00 a.m.
  • A replay of the conference call will be available shortly after the conclusion of the call and until May 7, 2024.

Danaher Schedules First Quarter 2024 Earnings Conference Call

Retrieved on: 
Thursday, March 21, 2024
Webcast, Danaher Corporation, Conference, DHR

WASHINGTON, March 21, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2024 on Tuesday, April 23, 2024 beginning at 8:00 a.m.

Key Points: 
  • WASHINGTON, March 21, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2024 on Tuesday, April 23, 2024 beginning at 8:00 a.m.
  • ET and notifying the operator that you are dialing in for Danaher's earnings conference call (Conference ID: DHRQ124).
  • A replay of the conference call will be available shortly after the conclusion of the call until May 7, 2024.
  • Danaher's earnings press release, the webcast slides and other related materials will be posted to the "Investors" section of Danaher's website under the subheading "Quarterly Earnings" beginning at 6:00 a.m.

DANAHER ALERT: Bragar Eagel & Squire, P.C. is Investigating Danaher Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, February 26, 2024
Biotechnology, Telephone, News, Biophysical environment, Growth, Projection, Vaccine, COVID-19, Danaher Corporation, DHR, Research, P.C, Pharmaceutical industry

Our investigation concerns whether the board of directors of Danaher have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Danaher have breached their fiduciary duties to the company.
  • Danaher designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide.
  • The Company is comprised of more than 20 operating companies organized under four segments: Biotechnology; Life Sciences; Diagnostics; and Environmental & Applied Solutions.
  • On April 25, 2023, Danaher issued a press release announcing its financial results for the first quarter of 2023.

Danaher to Present at TD Cowen Health Care Conference

Retrieved on: 
Tuesday, February 27, 2024
Danaher Corporation, DHR, Conference

WASHINGTON, Feb. 27, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the TD Cowen Healthcare Conference in Boston, Massachusetts on Tuesday, March 5, 2024 at 11:10 a.m.

Key Points: 
  • WASHINGTON, Feb. 27, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the TD Cowen Healthcare Conference in Boston, Massachusetts on Tuesday, March 5, 2024 at 11:10 a.m.
  • ET.
  • The event will be simultaneously webcast on www.danaher.com .

Danaher Commits to Set Science-Based, Net-Zero Greenhouse Gas Emission Reduction Targets

Retrieved on: 
Thursday, February 22, 2024
World Resources Institute, WRI, Climate, Targets, WWF, United Nations Global Compact, CDP, Health, Science Based Targets initiative, Danaher Corporation, DHR, Science, GHG, Partnership, Renewable energy

WASHINGTON, Feb. 22, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (Danaher) announced today it has committed to set science-based greenhouse gas (GHG) emission reduction targets in line with the Science Based Targets initiative (SBTi), including a long-term target to reach net-zero value chain emissions by no later than 2050.

Key Points: 
  • WASHINGTON, Feb. 22, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (Danaher) announced today it has committed to set science-based greenhouse gas (GHG) emission reduction targets in line with the Science Based Targets initiative (SBTi), including a long-term target to reach net-zero value chain emissions by no later than 2050.
  • Danaher's pledge encompasses Scope 1, 2 and 3 GHG emissions and complements its existing commitment to reduce Scope 1 and 2 GHG emissions on an absolute basis by 50.4% by 2032 compared to 2021.
  • "At the heart of everything we do at Danaher is continuous improvement, and our sustainability program further exemplifies this commitment," said Rainer M. Blair, Danaher's President and Chief Executive Officer.
  • Danaher will submit its GHG emission reduction targets to SBTi to be validated against the SBTi criteria.

Danaher Announces Quarterly Dividend

Retrieved on: 
Wednesday, February 21, 2024
Danaher Corporation, DHR

WASHINGTON, Feb. 21, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on April 26, 2024 to holders of record on March 28, 2024.

Key Points: 

WASHINGTON, Feb. 21, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on April 26, 2024 to holders of record on March 28, 2024.

Danaher Launches Collaboration with Cincinnati Children's Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development

Retrieved on: 
Monday, February 5, 2024
Health, Danaher Corporation, Hepatotoxicity, Failure, MD, Clinical trial, Therapy, Patient, FDA, Animal, Organoid, Molecular Devices, Developmental biology, DHR, Drug development, Risk, Biology, Tissue, Doctor of Philosophy, University, Liver, Custom, Pharmaceutical industry

Molecular Devices, a Danaher subsidiary and leading high-performance life science solutions provider, will build on a long-standing relationship with Cincinnati Children's to lead the Beacon's work. Molecular Devices is a pioneer of end-to-end solutions for organoid development, and recently launched the CellXpress.ai™ Automated Cell Culture System – an AI-enabled solution that automates demanding production schedules to produce reliable, reproducible, and streamlined organoids at scale. The Cincinnati Children's Center for Stem Cell & Organoid Medicine (CuSTOM) -- a cross-departmental multi-disciplinary center of excellence leveraging advances in developmental biology and stem cell technologies to create complex, physiologically functioning human tissues – has been producing organoids using Molecular Devices technology since 2019.

Key Points: 
  • Molecular Devices, a Danaher subsidiary and leading high-performance life science solutions provider, will build on a long-standing relationship with Cincinnati Children's to lead the Beacon's work.
  • William Blake, PhD, Chief Technology Officer, Human-Based R&D, Danaher, said: "Predictive, human-relevant drug safety testing is one of the most pressing needs to reduce clinical trial attrition.
  • Takebe said: "Our ongoing commitment to comprehending patient diversity and susceptibility to drug-related adverse events finds a synergistic match in our strategic collaboration with Danaher.
  • The collaboration with Cincinnati Children's is the latest addition to the Danaher Beacons program, which funds product-driven pioneering scientific research with globally recognized academic investigators.

Danaher Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Tuesday, January 30, 2024
Cepheid variable, DHR, Diagnosis, GAAP, Acquisition, Conference, Webcast, Proteomics, Danaher Corporation, Growth, Bank

WASHINGTON, Jan. 30, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2023.

Key Points: 
  • WASHINGTON, Jan. 30, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2023.
  • Non-GAAP core revenue decreased 11.5%, including a 4.5% non-GAAP base business core revenue decline.
  • For the first quarter 2024, the Company anticipates that non-GAAP core revenue will be down high-single digits year-over-year.
  • Danaher will discuss its fourth quarter results and financial guidance for the first quarter and full year 2024 during its quarterly investor conference call today starting at 8:00 a.m.

DANAHER ALERT: Bragar Eagel & Squire, P.C. is Investigating Danaher Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, January 29, 2024
Research, DHR, Biophysical environment, P.C, COVID-19, Telephone, Projection, Vaccine, News, Biotechnology, Danaher Corporation, Growth, Pharmaceutical industry

Our investigation concerns whether the board of directors of Danaher have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Danaher have breached their fiduciary duties to the company.
  • Danaher designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide.
  • The Company is comprised of more than 20 operating companies organized under four segments: Biotechnology; Life Sciences; Diagnostics; and Environmental & Applied Solutions.
  • On April 25, 2023, Danaher issued a press release announcing its financial results for the first quarter of 2023.